Bank of New York Mellon’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-227,843
| Closed | -$29.2M | – | 4181 |
|
|
2025
Q2 | $29.2M | Sell |
227,843
-79,175
| -26% | -$8.22M | 0.01% | 1311 |
|
|
2025
Q1 | $27.2M | Buy |
307,018
+3,586
| +1% | +$350K | 0.01% | 1324 |
|
|
2024
Q4 | $26.5M | Buy |
303,432
+7,101
| +2% | +$650K | ﹤0.01% | 1396 |
|
|
2024
Q3 | $27.4M | Buy |
296,331
+22,401
| +8% | +$2.23M | 0.01% | 1402 |
|
|
2024
Q2 | $29.5M | Buy |
273,930
+32,740
| +14% | +$3.28M | 0.01% | 1348 |
|
|
2024
Q1 | $22.9M | Sell |
241,190
-19,372
| -7% | -$1.66M | ﹤0.01% | 1499 |
|
|
2023
Q4 | $24M | Sell |
260,562
-6,182
| -2% | -$401K | ﹤0.01% | 1500 |
|
|
2023
Q3 | $13.4M | Buy |
266,744
+4,127
| +2% | +$221K | ﹤0.01% | 1772 |
|
|
2023
Q2 | $16.6M | Sell |
262,617
-940
| -0.4% | -$51.1K | ﹤0.01% | 1655 |
|
|
2023
Q1 | $11.9M | Buy |
263,557
+1,021
| +0.4% | +$46K | ﹤0.01% | 1839 |
|
|
2022
Q4 | $11.5M | Buy |
262,536
+2,789
| +1% | +$134K | ﹤0.01% | 1869 |
|
|
2022
Q3 | $17.1M | Buy |
259,747
+20,462
| +9% | +$1.31M | ﹤0.01% | 1594 |
|
|
2022
Q2 | $12.1M | Sell |
239,285
-7,976
| -3% | -$467K | ﹤0.01% | 1826 |
|
|
2022
Q1 | $15.8M | Sell |
247,261
-395,996
| -62% | -$28.4M | ﹤0.01% | 1814 |
|
|
2021
Q4 | $68.9M | Sell |
643,257
-43,629
| -6% | -$4.56M | 0.01% | 930 |
|
|
2021
Q3 | $70.6M | Sell |
686,886
-8,461
| -1% | -$788K | 0.01% | 890 |
|
|
2021
Q2 | $61.2M | Buy |
695,347
+23,977
| +4% | +$2.2M | 0.01% | 1001 |
|
|
2021
Q1 | $65.3M | Buy |
671,370
+168,834
| +34% | +$16.9M | 0.01% | 933 |
|
|
2020
Q4 | $56.4M | Buy |
502,536
+31,235
| +7% | +$3.29M | 0.01% | 971 |
|
|
2020
Q3 | $43.7M | Buy |
471,301
+18,834
| +4% | +$1.45M | 0.01% | 996 |
|
|
2020
Q2 | $35.3M | Buy |
452,467
+111,760
| +33% | +$7.56M | 0.01% | 1099 |
|
|
2020
Q1 | $19.9M | Buy |
340,707
+129,242
| +61% | +$8.32M | 0.01% | 1292 |
|
|
2019
Q4 | $16.9M | Buy |
211,465
+3,768
| +2% | +$282K | ﹤0.01% | 1667 |
|
|
2019
Q3 | $15.3M | Sell |
207,697
-5,676
| -3% | -$491K | ﹤0.01% | 1682 |
|
|
2019
Q2 | $20.1M | Buy |
213,373
+19,206
| +10% | +$1.59M | 0.01% | 1566 |
|
|
2019
Q1 | $15.5M | Buy |
194,167
+12,048
| +7% | +$890K | ﹤0.01% | 1707 |
|
|
2018
Q4 | $9.82M | Sell |
182,119
-9,976
| -5% | -$606K | ﹤0.01% | 1913 |
|
|
2018
Q3 | $15M | Buy |
192,095
+13
| +0% | +$904 | ﹤0.01% | 1812 |
|
|
2018
Q2 | $12.2M | Sell |
192,082
-12,591
| -6% | -$1M | ﹤0.01% | 1909 |
|
|
2018
Q1 | $18.8M | Buy |
204,673
+10,736
| +6% | +$925K | 0.01% | 1601 |
|
|
2017
Q4 | $14.6M | Buy |
193,937
+17,908
| +10% | +$1.26M | ﹤0.01% | 1776 |
|
|
2017
Q3 | $12.3M | Buy |
176,029
+1,326
| +0.8% | +$70.9K | ﹤0.01% | 1883 |
|
|
2017
Q2 | $8.85M | Buy |
174,703
+54,135
| +45% | +$2.3M | ﹤0.01% | 2038 |
|
|
2017
Q1 | $4.82M | Buy |
120,568
+27,095
| +29% | +$970K | ﹤0.01% | 2345 |
|
|
2016
Q4 | $2.62M | Buy |
93,473
+7,551
| +9% | +$228K | ﹤0.01% | 2692 |
|
|
2016
Q3 | $2.55M | Buy |
85,922
+15,172
| +21% | +$377K | ﹤0.01% | 2616 |
|
|
2016
Q2 | $1.43M | Buy |
70,750
+23,244
| +49% | +$422K | ﹤0.01% | 2908 |
|
|
2016
Q1 | $857K | Buy |
47,506
+7,089
| +18% | +$123K | ﹤0.01% | 3157 |
|
|
2015
Q4 | $1.06M | Buy |
40,417
+12,887
| +47% | +$290K | ﹤0.01% | 3133 |
|
|
2015
Q3 | $587K | Sell |
27,530
-5,486
| -17% | -$152K | ﹤0.01% | 3516 |
|
|
2015
Q2 | $874K | Buy |
+33,016
| New | +$943K | ﹤0.01% | 3413 |
|
Other funds holding BPMC
IA
HNB
Bank of New York Mellon's BPMC Position: Q3 2025 in Review
Bank of New York Mellon sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 227,843 shares — an estimated $29.2M sold.
Bank of New York Mellon first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $70.6M in Q3 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Bank of New York Mellon reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Bank of New York Mellon sold 227,843 Blueprint Medicines shares in Q3 2025, an estimated $29.2M.
- Bank of New York Mellon first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
- Bank of New York Mellon's Blueprint Medicines position peaked at $70.6M in Q3 2021.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Bank of New York Mellon's 13F filing for Q3 2025, filed 3 Nov 2025.